News

Fierce Biotech2d
Merck's leader in oral PCSK9 inhibitor race reduces cholesterol in pair of phase 3 trials
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...
Merck & Co. Inc. stock underperforms Wednesday when compared to competitors
The stock's fall snapped a three-day winning streak.
Fierce Pharma2d
Feeling RSV heat from Merck, Sanofi lays out early supply plans for Beyfortus
One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...
BioPharma Dive2d
Merck claims study success with PCSK9 cholesterol pill
Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...
Merck's potential blockbuster cholesterol pill succeeds in late-stage studies
Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...
Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials
Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety ...
Fierce Biotech8d
Merck made $3B-plus offer for MoonLake—and could revive interest in late-phase biotech: FT
Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...
Merck & Co., Inc. (MRK) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Merck & Co., Inc. ( NYSE: MRK) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:00 AM ET Dean Y. Li - Executive VP & President of Merck Research Laboratories Robert M. Davis - ...